Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1986 Oct;49(10):1182–1190. doi: 10.1136/jnnp.49.10.1182

Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study.

R Cantello, M Gilli, A Riccio, B Bergamasco
PMCID: PMC1029054  PMID: 3783180

Abstract

Fluctuations of mood and psychic activation were assessed in relation to "mobile" and "immobile" periods in 18 patients with Parkinson's disease presenting typical "end-of-dose deterioration". Twelve subjects with chronic but active rheumatoid arthritis presenting increased physical disability due to severe morning joint stiffness with a repetitive pattern of mobile and immobile periods acted as controls. The overall degree of disability and its fluctuations were close enough in the two groups for fair comparison of changes in affective behaviour. Temporary immobility was accompanied by adverse changes of mood and activation, which were significantly more marked in the Parkinson's disease group than in the controls, though to a lesser extent in those Parkinson's disease patients rated depressed even in their mobile periods. The possible correlation between mood changes and fluctuations of central dopaminergic function in the Parkinson's disease patients is discussed.

Full text

PDF
1182

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown R. G., Marsden C. D., Quinn N., Wyke M. A. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1984 May;47(5):454–465. doi: 10.1136/jnnp.47.5.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. CANTER G. J., DE LA TORRE R., MIER M. A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis. 1961 Aug;133:143–147. doi: 10.1097/00005053-196108000-00010. [DOI] [PubMed] [Google Scholar]
  3. Cantello R., Riccio A., Scarzella L., Leotta D., Bergamasco B. Depression in Parkinson disease: a disabling but neglected factor. Ital J Neurol Sci. 1984 Dec;5(4):417–422. doi: 10.1007/BF02042626. [DOI] [PubMed] [Google Scholar]
  4. Delis D., Direnfeld L., Alexander M. P., Kaplan E. Cognitive fluctuations associated with on-off phenomenon in Parkinson disease. Neurology. 1982 Sep;32(9):1049–1052. doi: 10.1212/wnl.32.9.1049. [DOI] [PubMed] [Google Scholar]
  5. Direnfeld L. K., Albert M. L., Volicer L., Langlais P. J., Marquis J., Kaplan E. Parkinson's disease. The possible relationship of laterality to dementia and neurochemical findings. Arch Neurol. 1984 Sep;41(9):935–941. doi: 10.1001/archneur.1984.04050200041016. [DOI] [PubMed] [Google Scholar]
  6. Fibiger H. C. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci. 1984 Feb;11(1 Suppl):105–107. doi: 10.1017/s0317167100046230. [DOI] [PubMed] [Google Scholar]
  7. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  8. Hachinski V. C., Iliff L. D., Zilhka E., Du Boulay G. H., McAllister V. L., Marshall J., Russell R. W., Symon L. Cerebral blood flow in dementia. Arch Neurol. 1975 Sep;32(9):632–637. doi: 10.1001/archneur.1975.00490510088009. [DOI] [PubMed] [Google Scholar]
  9. Hardie R. J., Lees A. J., Stern G. M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 1984 Jun;107(Pt 2):487–506. doi: 10.1093/brain/107.2.487. [DOI] [PubMed] [Google Scholar]
  10. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  11. Javoy-Agid F., Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology. 1980 Dec;30(12):1326–1330. doi: 10.1212/wnl.30.12.1326. [DOI] [PubMed] [Google Scholar]
  12. Klein D. F. Endogenomorphic depression. A conceptual and terminological revision. Arch Gen Psychiatry. 1974 Oct;31(4):447–454. doi: 10.1001/archpsyc.1974.01760160005001. [DOI] [PubMed] [Google Scholar]
  13. Korf J., van Praag H. M. Retarded depression and the dopamine metabolism. Psychopharmacologia. 1971;19(2):199–203. doi: 10.1007/BF00402643. [DOI] [PubMed] [Google Scholar]
  14. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  15. Mayeux R., Stern Y., Cote L., Williams J. B. Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology. 1984 May;34(5):642–646. doi: 10.1212/wnl.34.5.642. [DOI] [PubMed] [Google Scholar]
  16. Mayeux R., Stern Y., Rosen J., Leventhal J. Depression, intellectual impairment, and Parkinson disease. Neurology. 1981 Jun;31(6):645–650. doi: 10.1212/wnl.31.6.645. [DOI] [PubMed] [Google Scholar]
  17. Nutt J. G., Carter J. H. Sensory symptoms in parkinsonism related to central dopaminergic function. Lancet. 1984 Aug 25;2(8400):456–457. doi: 10.1016/s0140-6736(84)92924-6. [DOI] [PubMed] [Google Scholar]
  18. Robins A. H. Depression in patients with Parkinsonism. Br J Psychiatry. 1976 Feb;128:141–145. doi: 10.1192/bjp.128.2.141. [DOI] [PubMed] [Google Scholar]
  19. Schwab J., Bialow M., Clemmons R., Martin P., Holzer C. The Beck depression inventory with medical inpatients. Acta Psychiatr Scand. 1967;43(3):255–266. doi: 10.1111/j.1600-0447.1967.tb05762.x. [DOI] [PubMed] [Google Scholar]
  20. Serra G., Argiolas A., Klimek V., Fadda F., Gessa G. L. Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci. 1979 Jul 30;25(5):415–423. doi: 10.1016/0024-3205(79)90573-3. [DOI] [PubMed] [Google Scholar]
  21. Shoulson I., Glaubiger G. A., Chase T. N. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology. 1975 Dec;25(12):1144–1148. doi: 10.1212/wnl.25.12.1144. [DOI] [PubMed] [Google Scholar]
  22. Stern Y., Mayeux R., Rosen J. Contribution of perceptual motor dysfunction to construction and tracing disturbances in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1984 Sep;47(9):983–989. doi: 10.1136/jnnp.47.9.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tolosa E. S., Martin W. E., Cohen H. P., Jacobson R. L. Patterns of clinical response and plasma dopa levels in Parkinson's disease. Neurology. 1975 Feb;25(2):177–183. doi: 10.1212/wnl.25.2.177. [DOI] [PubMed] [Google Scholar]
  24. Van Kammen D. P., Murphy D. L. Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment. Psychopharmacologia. 1975 Nov 21;44(3):215–224. doi: 10.1007/BF00428897. [DOI] [PubMed] [Google Scholar]
  25. Yokel R. A., Wise R. A. Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology (Berl) 1976 Aug 17;48(3):311–318. doi: 10.1007/BF00496868. [DOI] [PubMed] [Google Scholar]
  26. Zaphiropoulos G., Burry H. C. Depression in rheumatoid disease. Ann Rheum Dis. 1974 Mar;33(2):132–135. doi: 10.1136/ard.33.2.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. van Praag H. M. Depression. Lancet. 1982 Dec 4;2(8310):1259–1264. doi: 10.1016/s0140-6736(82)90115-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES